News & Updates
Filter by Specialty:
Ustekinumab safe, effective in Asians with severe plaque psoriasis
Ustekinumab, a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, demonstrates effectiveness and safety in the treatment of multiethnic Asian patients with moderate to severe plaque psoriasis, according to a Singapore study.
Ustekinumab safe, effective in Asians with severe plaque psoriasis
04 Mar 2022Ligelizumab improves symptoms, QoL in patients with urticaria
In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.
Ligelizumab improves symptoms, QoL in patients with urticaria
02 Mar 2022Worse joint pain in psoriasis patients with PsA boosts analgesic use
Psoriasis patients, especially those with concomitant psoriatic arthritis (PsA), suffer from worse joint pain, leading to higher analgesic use rates than the general population, a recent study has found.
Worse joint pain in psoriasis patients with PsA boosts analgesic use
27 Feb 2022Dual inhibition of LAG-3, PD-1: a new therapeutic target for advanced melanoma?
In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.
Dual inhibition of LAG-3, PD-1: a new therapeutic target for advanced melanoma?
25 Feb 2022AI as good as experts at detecting melanomas
Convolutional neural networks (CNN) can outperform less-experienced pathologists at discriminating melanomas from nevi, reports a recent study. For experienced pathologists, CNNs may still be helpful as a form of triage.